MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED 美瑞健康國際產業集團有限公 司 (Incorporated in Bermuda with limited liability) (Stock Code 股份代號：2327) （於百慕達註冊成立之有限公司） NOTIFICATION LETTER 通知信函 22 September 2025 Dear Shareholders Meilleure Health International Industry Group Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") English and Chinese versions of the Current Corporate Communication are available under the Investor Relations section of the Company's ...

Financial Performance - Revenue for the six months ended June 30, 2025, was approximately HKD 17.5 million, a decrease of about 41.7% from HKD 30.0 million for the same period in 2024[13] - Gross profit for the same period was approximately HKD 14.2 million, down about 7.8% from HKD 15.4 million in 2024, with a gross margin increase from 51.3% to 81.1%[16] - Other income and net gains for the six months ended June 30, 2025, were approximately HKD 22.6 million, a decrease of about 30.7% from HKD 32.6 million in 2024[17] - Profit after tax for the six months ended June 30, 2025, was approximately HKD 15.1 million, an increase of about 84.1% from HKD 8.2 million in 2024[20] - The decline in revenue was primarily due to a decrease in sales of construction materials by approximately HKD 8.7 million and health-related products by approximately HKD 3.5 million[13] - The increase in gross margin was attributed to a lower proportion of revenue from the trading business, which has a lower gross margin compared to other business segments[16] - Interest income rose from approximately HKD 8.9 million in 2024 to approximately HKD 14.8 million in 2025, contributing to the overall financial performance[17] - The group reported a loss of approximately HKD 1.0 million in the trade business for the six months ended June 30, 2025, compared to a profit of approximately HKD 66,000 for the same period in 2024, a decline of about 115.2%[24] Assets and Liabilities - Non-current assets increased to approximately HKD 999.0 million as of June 30, 2025, from HKD 980.4 million as of December 31, 2024, an increase of about HKD 18.6 million[29] - Current assets rose to approximately HKD 750.1 million as of June 30, 2025, from HKD 688.3 million as of December 31, 2024, an increase of about HKD 61.8 million[29] - Total liabilities increased to approximately HKD 530.1 million as of June 30, 2025, from HKD 467.3 million as of December 31, 2024, an increase of about HKD 62.8 million[30] - The group’s net asset value as of June 30, 2025, was approximately HKD 1,218.9 million, compared to HKD 1,201.4 million as of December 31, 2024[27] - As of June 30, 2025, the total outstanding loans receivable amounted to HKD 505,383,000, with the largest borrower, Guangyu Zhaoneng, accounting for 43.3% of the total at HKD 219,160,000[53] Cash Flow - The net cash used in operating activities for the six months ended June 30, 2025, was approximately HKD 13.4 million, compared to a net cash inflow of HKD 109.3 million for the same period in 2024[32][33] - The net cash used in investing activities was approximately HKD 22.1 million, mainly due to short-term interest-bearing loans of approximately HKD 39.1 million issued to independent third parties, partially offset by interest income of approximately HKD 13.0 million[33] - The net cash generated from financing activities was approximately HKD 15.1 million, primarily from new bank loans of approximately HKD 48.3 million, offset by loan repayments of approximately HKD 19.3 million and share buybacks of approximately HKD 8.9 million[34] Shareholder Information - The board has declared an interim dividend of HKD 0.15 per share for the six months ending June 30, 2025, totaling approximately HKD 6,141,000[86] - The interim dividend will be paid on October 31, 2025, to shareholders listed on October 2, 2025[86] - The company repurchased a total of 29,706,000 shares at a total cost of HKD 8,847,264[120] Employee and Management - As of June 30, 2025, the group had a total of 49 employees, an increase from 46 employees as of December 31, 2024[62] - The company is committed to employee training and development to align with strategic goals and customer requirements[63] Market and Industry Trends - The health industry in China is projected to reach a market size of over RMB 16 trillion by 2030, indicating significant growth potential[66] - By the end of 2024, the population aged 60 and above in China is expected to reach 310 million, accounting for 22% of the total population, driving demand in the health sector[67] - The "silver economy" market size has surpassed RMB 9 trillion, reflecting the growing needs of the aging population[67] - The health industry is experiencing rapid growth due to increased consumer demand for preventive medicine and personalized health management[67] Strategic Focus - The company continues to believe in the significant potential of the health industry, focusing on leveraging technology and professional services to enhance health and beauty[45] - The company is focusing on the development of cell therapy and health management businesses, leveraging its extensive experience in skin health management[68] - The company aims to optimize its product offerings by combining skincare products with medical aesthetics, enhancing effectiveness in skin health management[68] Research and Development - The company has made strategic investments in the cell therapy sector, including a strategic stake in a national high-tech enterprise in 2019 and the establishment of a new entity in 2020 focused on cell immunotherapy[71] - The company has been granted multiple patents related to stem cell preparation methods and artificial intelligence monitoring systems, enhancing its technological capabilities[72] - The company is actively involved in clinical collaborations with several medical institutions to accelerate the clinical translation of scientific achievements[72] Corporate Governance - The company has adopted the principles of the Corporate Governance Code and complied with all applicable code provisions[125] - The board of directors confirmed compliance with the standards set out in the Model Code for Securities Transactions by Directors[126] - The audit committee reviewed the group's accounting principles and practices, including the unaudited interim financial information for the six months ended June 30, 2025[127]

Core Insights - The latest shareholder equity disclosures for Mei Rui Health International, Huaxin Cement, and Yingxing Holdings were made on September 15, 2025 [1] Group 1: Mei Rui Health International (02327) - Shunda Investment increased its holdings from 2.322 billion shares to 2.328 billion shares, representing a holding percentage change from 56.71% to 56.86% [2] - Zhongjia U-Home Investment Limited raised its stake from 1.357 billion shares to 1.364 billion shares, with a holding percentage change from 33.16% to 33.31% [2] - Yuan Yakang and Shenzhen Kangchengheng Capital both reduced their holdings from 42.02 million shares to 40.69 million shares, resulting in a holding percentage change from 13.24% to 12.82% [2] - HHLR Advisors, Ltd. decreased its holdings from 8.3232 million shares to 7.7254 million shares, with a holding percentage change from 5.34% to 4.95% [2] Group 2: Huaxin Cement (06655) - Ming Jinhua increased his holdings from 189,300 shares to 209,800 shares, maintaining a holding percentage of 0.03% [2] Group 3: Yingxing Holdings (01440) - Liang Bingde acquired 50,000 shares, marking a new holding with a percentage of 0.01% [2]

Group 1 - The core point of the article highlights the recent stock transfer of Meirui Health International from CITIC Securities Hong Kong to Minyin Securities, with a market value of HKD 106 million, representing 9.41% of the total shares [1] - Meirui Health International reported its interim results for the six months ending June 30, 2025, showing a revenue of HKD 17.453 million, a year-on-year decrease of 41.89% [1] - The profit attributable to the company's owners was HKD 15.157 million, reflecting a year-on-year increase of 79.05%, with earnings per share at HKD 0.37 [1]

Core Viewpoint - Shareholders of Meirui Health International (02327) transferred stocks from CITIC Securities Hong Kong to Minyin Securities, with a transfer market value of HKD 106 million, accounting for 9.41% of the total shares [1] Financial Performance - For the six months ending June 30, 2025, Meirui Health International reported revenue of HKD 17.453 million, a year-on-year decrease of 41.89% [1] - The profit attributable to the company's owners was HKD 15.157 million, reflecting a year-on-year increase of 79.05% [1] - Earnings per share were reported at HKD 0.037 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美瑞健康國際產業集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02327 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - 美瑞健康国际 reported a significant decline in revenue for the six months ending June 30, 2025, with a total revenue of HKD 17.453 million, representing a year-on-year decrease of 41.9% [1] Financial Performance - Revenue for the period was HKD 17.453 million, down 41.9% year-on-year [1] - Gross profit amounted to HKD 14.161 million, reflecting a decrease of 8% compared to the previous year [1] - Profit attributable to owners of the company was HKD 15.157 million, which is an increase of 79.1% year-on-year [1] - Basic earnings per share were HKD 0.0037, with a proposed interim dividend of HKD 0.0015 per share [1]

Core Viewpoint - 美瑞健康国际 (02327) reported a decrease in revenue but an increase in profit attributable to shareholders for the six months ending June 30, 2025, indicating a mixed financial performance [1] Financial Performance - The company achieved revenue of 17.453 million HKD, a year-on-year decrease of 41.89% [1] - Profit attributable to shareholders was 15.157 million HKD, a year-on-year increase of 79.05% [1] - Earnings per share stood at 0.37 HKD [1] Profit Analysis - The after-tax profit for the six months ending June 30, 2025, was approximately 15.10 million HKD, compared to 8.20 million HKD for the same period in 2024, reflecting an increase of about 6.90 million HKD or approximately 84.1% [1] Revenue Drivers - The increase in profit was primarily due to: - Growth in property-related business revenue and profit, with rental income rising from approximately 8.20 million HKD to about 10.00 million HKD [1] - Interest income increased from approximately 8.90 million HKD to about 14.80 million HKD [1] - Positive financial impact from foreign exchange gains, which rose from approximately 4.40 million HKD to about 5.80 million HKD [1]

Core Viewpoint - Meizhou Health International (02327) reported a mixed performance for the six months ending June 30, 2025, with a significant decrease in revenue but a notable increase in profit attributable to shareholders [1] Financial Performance - The company achieved revenue of HKD 17.453 million, a year-on-year decrease of 41.89% [1] - Profit attributable to shareholders was HKD 15.157 million, reflecting a year-on-year increase of 79.05% [1] - Earnings per share stood at HKD 0.37 [1] Profit Analysis - The after-tax profit for the six months ending June 30, 2025, was approximately HKD 15.1 million, up about HKD 6.9 million or approximately 84.1% compared to HKD 8.2 million for the same period in 2024 [1] - The increase in profit was primarily due to: - Growth in property-related business revenue and profit, with rental income rising from approximately HKD 8.2 million to about HKD 10 million [1] - Interest income increased from approximately HKD 8.9 million to about HKD 14.8 million [1] - Positive financial impact from foreign exchange gains, which rose from approximately HKD 4.4 million to about HKD 5.8 million [1]

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 美瑞健康國際產業集團有限公司 | | 股份代號 | 02327 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.0015 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.0015 HKD | | 匯率 | 1 HKD ...